Elevance beats estimates, raises profit outlook, but shares fall on weak guide

Elevance Health raised its 2026 adjusted profit outlook to at least $27 a share after posting second-quarter operating revenue of $49.8 billion and adjusted diluted earnings of $7.45, yet the stock fell nearly 9% before the open as investors questioned whether the update was strong enough to calm the market.

The company’s second quarter was helped by better medical cost management and improved operating performance, but it also carried an approximately $0.80-per-share net below-the-line benefit that helped lift reported results. Net income came to about $1.45 billion. For investors trying to judge the underlying trend, that detail mattered more than the headline beat because it raised the question of how much of the quarter was driven by durable margin improvement versus one-time help.

Elevance also said it would lift 2026 operating cash flow guidance to at least $6.0 billion and end the quarter with about 44.9 million medical members. Even so, Wall Street focused on the pressure points: the Health Benefits segment, shifting member mix and persistent anxiety that medical utilization could stay elevated across the managed-care industry. Shares of Molina Healthcare, Centene and Oscar Health also traded lower after the update, underscoring that the reaction was not just about one company.

Management responded by leaning into a narrower, more selective strategy. Elevance said it reached a mutual agreement to exit Washington, D.C.’s Medicaid managed care program effective Aug. 1 and expects to leave additional Medicaid markets over the next 12 to 18 months where it does not see sustainable performance. Executives said national Medicaid membership was about 8.4 million as of June 30, down 4.3% from a year earlier. That signals a willingness to give up weaker business rather than chase volume that does not earn acceptable returns.

Gail Boudreaux, Elevance’s chair, president and chief executive, cast the quarter as disciplined execution. Chief Financial Officer Mark Kaye said the outlook reflected elevated but understood trends, improving rate alignment and targeted cost actions already underway. The company also said it is increasing investment in medical cost management, member experience, provider connectivity, operating efficiency and Carelon’s value-based solutions, a sign that it wants to defend margins without appearing to retreat from service or care management. Elevance said it sees 2027 adjusted EPS growth of at least 12% off a re-established 2026 baseline of at least $26, but the market’s immediate response suggested investors want proof that insurer margins can hold before they reward the higher guide.